540
Participants
Start Date
October 13, 2015
Primary Completion Date
February 28, 2019
Study Completion Date
February 28, 2022
HeartMate 3
Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
Institute for Clinical and Experimental Medicine (IKEM), Prague
AJH - Wien, Vienna
Rigshospitalet Copenhagen, Copenhagen
Erasmus MC - Thoraxcenter, Rotterdam
UMC Utrecht, Utrecht
Deutsches Herzzentrum Berlin, Berlin
Ospedale San Raffaele, Milan
Universitätsklinikum Schleswig Holstein, Lübeck
Medizinische Hochschule Hannover, Hanover
Herz-und Diabetes Zentrum NRW, Bad Oeynhausen
Ospedale Civile Maggiore di Verona Borgo Trento, Verona
Otto-von-Guericke-Universitat Magdeburg, Magdeburg
Medizinische Einrichtungen der Universitat Dusseldorf, Düsseldorf
Universitatsklinikum Aachen, Aachen
Sheba Medical Center, Tel Aviv
Universitätsklinikum Tübingen, Tübingen
Universitäts-Herzzentrum Freiburg, Freiberg
Herz- und Gefäßklinik Bad Neustadt a d Saale, Bad Neustadt an der Saale
National Heart Centre Singapore, Singapore
Universitätsklinikum Jena, Jena
Herzentrum Leipzig GmbH, Leipzig
Az. Osp. San Camillo Forlanini, Roma
National Research Center for Cardiac Surgery, Astana
Warsaw Institute of Cardiology, Warsaw
Queen Elizabeth Hospital, Birmingham
Wythenshawe Hospital, Manchester
Lead Sponsor
Thoratec Europe Ltd
INDUSTRY
Thoratec Corporation
INDUSTRY
Abbott Medical Devices
INDUSTRY